What are your expectations for the strategic update this...

What are your expectations for the strategic update this quarter?

My thoughts are broadly a road map to commercialisation. We have seen hints of this in the H1 update and letter to shareholders, so just formalising the strategy.

Speculation at its finest:

1. EMD AML P2 to be pursued under the new RC220 formulation in EUR. Could lead to EMA approval initially rather than FDA, really because Astex have a focus in EUR so driven more by them than Race.

Question: As RC220 will be used is the US IND that so much effort was spent on now obsolete?

2. Cardio protect seems to be driven by US KOL input, once governance approval for P2 get data for US IND and apply for breakthrough therapy designation. Partner for US pivitol trial.

Question: Timelines and costing are the focus is it a 5 year $50m project. Want to see an innovative solution not just Cap Raise and delays.

3. Recent FTO collaboration with COH to be consolidated, indication for trial to be selected. Melanoma, ccRCC or Lung cancer / other as driven by 100+ results and COH data to be the indication of choice.

Question: When using a proof of concept trial for FTO target is a pan tumour trial the way to go, or, a single cancer indication - in order to prove Bisantrene as a FTO inhibitor as a platform therapy?

In summary, would like to understand. Strategy for each pillar for commercialisation, funding and timeframes. 5-Path strategy was pivotal for Race’s scientific footprint we need this to be focused on commercialisation.

Will be interested to see the developments!